Case ReportsResponse to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case reportWu, Chao,*; Fan, Mengjiao,*; Hu, Yi Author Information Department of Oncology, Chinese PLA General Hospital, Beijing, China *Chao Wu and Mengjiao Fan contributed equally to this work as co-first authors. Received 19 June 2021 Revised form accepted 21 June 2021 Correspondence to Yi Hu, PhD, Department of Oncology, Chinese PLA General Hospital, Beijing 100853, China, Tel: +86 10 66937875; e-mail: [email protected] Anti-Cancer Drugs 33(1):p e734-e737, January 2022. | DOI: 10.1097/CAD.0000000000001160 Buy Metrics Abstract Mutation of BRCA2, a breast cancer susceptibility gene, is associated with the development of breast and ovarian cancer. Olaparib is an oral poly-adenosine diphosphate–ribose polymerase (PARP) inhibitor, which has been proven to treat BRCA-mutated tumors effectively, especially breast and ovarian cancer. Here, we report a case of a germline BRCA2-mutated metastatic lung adenocarcinoma, non–small-cell lung cancer, responded well to olaparib. A 41-year-old man with no history of smoking was diagnosed with advanced lung adenocarcinoma. The patient was treated with bevacizumab, pemetrexed disodium, and cis-platinum in the first-line therapy of 6 months, followed by bevacizumab, Abraxane, and sintilimab treatments for another 6 months. As disease progression was confirmed and the presence of germline BRCA2 mutation, the combinational treatment of olaparib/anlotinib was applied to achieve partial response 1 month later, and the progression-free survival was extended for another 5 months. This study shows metastatic lung adenocarcinoma with BRCA2 mutation could also respond well to PARP inhibitor, broadening the spectrum of BRCA-mutated cancers suitable for olaparib therapy. With acquired resistance to chemotherapy, bevacizumab, and immunotherapy, the patient still gained significant benefits from the targeted therapy. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.